Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.15 SEK | +0.75% | +3.32% | +30.98% |
May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Sales 2024 * | 611M 58.17M | Sales 2025 * | 750M 71.32M | Capitalization | 689M 65.55M |
---|---|---|---|---|---|
Net income 2024 * | -67M -6.37M | Net income 2025 * | -31M -2.95M | EV / Sales 2024 * | 1.54 x |
Net Debt 2024 * | 251M 23.88M | Net Debt 2025 * | 150M 14.27M | EV / Sales 2025 * | 1.12 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-21.5
x | Employees | 116 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.72% |
Latest transcript on Orexo AB
1 day | +0.75% | ||
1 week | +3.32% | ||
Current month | +1.25% | ||
1 month | +11.02% | ||
3 months | +21.84% | ||
6 months | +33.40% | ||
Current year | +30.98% |
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 11-09-30 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 22-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-04-10 | |
James Noble
CHM | Chairman | 65 | 20-04-15 |
Director/Board Member | 62 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 20.25 | +1.25% | 31 521 |
24-05-31 | 20 | -5.21% | 29,394 |
24-05-30 | 21.1 | -2.31% | 18,435 |
24-05-29 | 21.6 | +1.65% | 11,418 |
24-05-28 | 21.25 | +8.42% | 29,566 |
Delayed Quote Nasdaq Stockholm, June 03, 2024 at 05:58 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.98% | 65.41M | |
+16.10% | 78.51B | |
+13.10% | 9B | |
+58.17% | 4.96B | |
-14.94% | 4.84B | |
-.--% | 3.72B | |
-26.63% | 2.19B | |
+16.75% | 2.12B | |
-37.97% | 1.94B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- ORX Stock